Navigation Links
Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
Date:9/23/2008

AURORA, Ontario, Sept. 23 /PRNewswire/ -- Helix BioPharma announced today that Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., will be presenting L-DOS47 research findings at the National Research Council of Canada's (NRC) Eighth Annual General Meeting of the Genomics and Health Initiative, today in Saskatoon, Saskatchewan, Canada. The meeting includes Canadian researchers from across the NRC, government departments and private industry and covers diverse topics in genomics research.

Dr. Chao's presentation, titled "L-DOS47: Targeting the Tumor Microenvironment with an Immunoconjugate" will provide a summary of selected previously announced L-DOS47 research findings. "We are very pleased to have been invited to participate in this important scientific forum," said Dr. Chao. "It is an excellent opportunity to showcase our findings to Canada's research community as we continue to advance our L-DOS47 development program.

For additional information on the Genomics and Health Initiative conference, please visit: http://www.pbi.nrc.ca/ghi-agm.htm .

About L-DOS47

L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimul
'/>"/>

SOURCE Helix BioPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
(Date:3/25/2015)... SHANGHAI , CAMBRIDGE, Mass. and ... -- WuXi NextCODE, which provides comprehensive capabilities for using the ... deCODE genetics on their publication of the largest studies of ... published today online in Nature Genetics ... date of sequence variation, authored by a team of deCODE ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... 2012  Patients with gynecologic cancer have new hope in ... Center at University Hospitals (UH) Case Medical Center.  A ... is among the first in the nation to launch ... treat ovarian, endometrial and select other cancers. ...
... N.J., Jan. 20, 2012  Insmed Incorporated (Nasdaq CM: ... U.S. Food and Drug Administration (FDA) has lifted ... amikacin for inhalation) in patients with non-tuberculous mycobacteria ... discussions with FDA regarding the clinical hold placed ...
... N.Y., Jan. 19, 2012  Netsmart, the leading provider ... organizations nationwide, today announced the launch of ... highlight the positive clinical and financial impacts provided ... (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO ) In ...
Cached Biology Technology:UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 2UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients 3Insmed Incorporated Provides Corporate Update 2Insmed Incorporated Provides Corporate Update 3EveryDayMatters.com Aims to Raise Awareness and Coordinate Care Between Mental and Physical Health 2EveryDayMatters.com Aims to Raise Awareness and Coordinate Care Between Mental and Physical Health 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... that in which they exist naturally, proteins and multiprotein ... they exhibit when in the static form in which ... College of Medicine in a report in the current ... study using electron cryomicroscopy, Dr. Steven Ludtke, assistant professor ...
... place is not a Rudyard Kipling “Just So?story, but an ... results. For a chicken, it’s the difference between having feathers ... of Southern California and mathematicians at Oxford University in the ... To understand patterning on the molecular and the systems level, ...
... novel way of combating diseases related to the immune system, ... and arthritis. The study, funded by the Wellcome Trust, appears ... by the body to fight infection. Scientists previously identified two ... T cells", which attack infected cells, and "regulatory T cells", ...
Cached Biology News:Embryonic patterning makes the feathers fly 2T for two: Scientists show how immune system chooses best way to fight infection 2
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Luminometers...
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Biology Products: